Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Martin

Interventional Pain Medicine Meridian, MS Medical Doctor

NPI 1124412234 CMS profile 5701470

1001 14Th St, Meridian, MS 39301

Open in the dashboard

General payments

$18,469

321 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Martin of Meridian, MS is reported in the CMS Open Payments database as having received $18,469 across 321 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,365 70
2024 General $2,305 45
2023 General $3,009 49
2022 General $4,672 54
2021 General $2,571 46
2020 General $2,680 42
2019 General $1,869 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Martin
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Charles Martin were reported at $1,365. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Charles Martin Interventional Pain Medicine median Middle half National median
2019 $1,869 $684 $216–$2,079 $163
2020 $2,680 $382 $122–$1,109 $114
2021 $2,571 $552 $167–$1,554 $132
2022 $4,672 $605 $187–$1,924 $149
2023 $3,009 $671 $195–$1,915 $160
2024 $2,305 $684 $206–$1,837 $164
2025 $1,365 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $8,270 132 payments
  2. Boston Scientific Corporation $4,470 83 payments
  3. Relievant Medsystems, Inc. $1,939 15 payments
  4. Spinal Simplicity, LLC $1,618 21 payments
  5. Medtronic, Inc. $995 26 payments
  6. Foundation Fusion Solutions, LLC $336 3 payments
  7. COMSORT, Inc $100 1 payment
  8. Stryker Corporation $92 3 payments
  9. Collegium Pharmaceutical, Inc. $78 5 payments
  10. BIOTRONIK NRO, Inc. $77 3 payments
  11. Other $493 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,428 301 payments
  2. Travel and Lodging $3,942 19 payments
  3. Consulting Fee $100 1 payment
Products named General payments · program years 2019–2025
  1. Proclaim Family of SCS IPGs $2,750 33 payments
  2. Proclaim IPG $2,199 31 payments
  3. Intracept Pain $2,083 18 payments
  4. Intracept Pain $1,939 15 payments
  5. Intracept Pain $1,939 15 payments
  6. Intracept Pain $1,939 15 payments
  7. PROCLAIM $1,931 37 payments
  8. HA MINUTEMAN G3-R $1,618 21 payments
  9. Superion Indirect Decompression System $929 5 payments
  10. SPECTRA WAVEWRITER $799 5 payments
  11. Other $5,176 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

84

Median for Anesthesiology: 322

Drug cost

$1,244

Median for Anesthesiology: $8,738

Branded share of claims

70.2%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 45 $501
Morphine Sulfate Er Morphine Sulfate Brand 14 $356
Oxycodone Hcl Generic 13 $346
Gabapentin Generic 12 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$192,163

Of which drugs: $2,303

Medicare patients

449

Average age 73

Services billed

1,932

279 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 40%
Depression 35%
Ischemic heart disease 34%
Chronic kidney disease 26%
COPD 25%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 80 $59

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

321 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record